Cargando…

Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers

In liver fibrosis, conversion of fibroblasts to profibrogenic myofibroblasts significantly drives the development of the disease. A crucial role of cyclic adenosine monophosphate (cAMP) in regulation of fibroblast function has been reported. Increase in cAMP levels has been found to decrease fibrobl...

Descripción completa

Detalles Bibliográficos
Autores principales: El Awdan, Sally A., Abdel Rahman, Rehab F., Ibrahim, Heba M., Hegazy, Rehab R., El Marasy, Salma A., Badawi, Manal, Arbid, Mahmoud S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505801/
https://www.ncbi.nlm.nih.gov/pubmed/31067255
http://dx.doi.org/10.1371/journal.pone.0216301
_version_ 1783416814595735552
author El Awdan, Sally A.
Abdel Rahman, Rehab F.
Ibrahim, Heba M.
Hegazy, Rehab R.
El Marasy, Salma A.
Badawi, Manal
Arbid, Mahmoud S.
author_facet El Awdan, Sally A.
Abdel Rahman, Rehab F.
Ibrahim, Heba M.
Hegazy, Rehab R.
El Marasy, Salma A.
Badawi, Manal
Arbid, Mahmoud S.
author_sort El Awdan, Sally A.
collection PubMed
description In liver fibrosis, conversion of fibroblasts to profibrogenic myofibroblasts significantly drives the development of the disease. A crucial role of cyclic adenosine monophosphate (cAMP) in regulation of fibroblast function has been reported. Increase in cAMP levels has been found to decrease fibroblast proliferation, inhibit their conversion to myofibroblast, and stimulate their death. cAMP is generated by adenyl cyclase (AC), and degraded by cyclic nucleotide phosphodiesterase (PDE). In this study, the antifibrotic effect of a PDE inhibitor, cilostazol (Cilo), on a rat model of liver fibrosis induced by thioacetamide (TAA) was investigated. Four groups of rats were used; the first group received the vehicles and served as the normal control group, while liver fibrosis was induced in the other groups using (TAA, 200 mg/kg/biweekly for 8 successive weeks, ip). The last two groups were treated with Cilo (50 and 100 mg/kg/day, po, respectively). Induction of liver fibrosis in TAA-treated rats was observed as evidenced by the biochemical and histopathological findings. On the other hand, a potent antifibrotic effect was observed in the groups treated with Cilo, with preference to the higher dose. In these groups, a significant increase in the liver content of cAMP was demonstrated that was accompanied by reduction in the hepatic expression of key fibrogenic cytokines, growth factors, and inflammatory biomarkers, including interleukin-6, tumor necrosis factor-alpha, nuclear factor kappa B, and transforming growth factor-beta as compared to TAA group. Moreover, amelioration of TAA-induced oxidative stress and apoptosis in the liver has been observed. These findings reveal the antifibrotic effect of Cilo against TAA-induced liver fibrosis in rats, and suggest regulation of cAMP pathway, together with the modulation of oxidative stress, inflammation, and apoptosis as mechanistic cassette underlines this effect.
format Online
Article
Text
id pubmed-6505801
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65058012019-05-23 Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers El Awdan, Sally A. Abdel Rahman, Rehab F. Ibrahim, Heba M. Hegazy, Rehab R. El Marasy, Salma A. Badawi, Manal Arbid, Mahmoud S. PLoS One Research Article In liver fibrosis, conversion of fibroblasts to profibrogenic myofibroblasts significantly drives the development of the disease. A crucial role of cyclic adenosine monophosphate (cAMP) in regulation of fibroblast function has been reported. Increase in cAMP levels has been found to decrease fibroblast proliferation, inhibit their conversion to myofibroblast, and stimulate their death. cAMP is generated by adenyl cyclase (AC), and degraded by cyclic nucleotide phosphodiesterase (PDE). In this study, the antifibrotic effect of a PDE inhibitor, cilostazol (Cilo), on a rat model of liver fibrosis induced by thioacetamide (TAA) was investigated. Four groups of rats were used; the first group received the vehicles and served as the normal control group, while liver fibrosis was induced in the other groups using (TAA, 200 mg/kg/biweekly for 8 successive weeks, ip). The last two groups were treated with Cilo (50 and 100 mg/kg/day, po, respectively). Induction of liver fibrosis in TAA-treated rats was observed as evidenced by the biochemical and histopathological findings. On the other hand, a potent antifibrotic effect was observed in the groups treated with Cilo, with preference to the higher dose. In these groups, a significant increase in the liver content of cAMP was demonstrated that was accompanied by reduction in the hepatic expression of key fibrogenic cytokines, growth factors, and inflammatory biomarkers, including interleukin-6, tumor necrosis factor-alpha, nuclear factor kappa B, and transforming growth factor-beta as compared to TAA group. Moreover, amelioration of TAA-induced oxidative stress and apoptosis in the liver has been observed. These findings reveal the antifibrotic effect of Cilo against TAA-induced liver fibrosis in rats, and suggest regulation of cAMP pathway, together with the modulation of oxidative stress, inflammation, and apoptosis as mechanistic cassette underlines this effect. Public Library of Science 2019-05-08 /pmc/articles/PMC6505801/ /pubmed/31067255 http://dx.doi.org/10.1371/journal.pone.0216301 Text en © 2019 El Awdan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
El Awdan, Sally A.
Abdel Rahman, Rehab F.
Ibrahim, Heba M.
Hegazy, Rehab R.
El Marasy, Salma A.
Badawi, Manal
Arbid, Mahmoud S.
Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
title Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
title_full Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
title_fullStr Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
title_full_unstemmed Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
title_short Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
title_sort regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: up regulation of hepatic camp, and modulation of inflammatory, oxidative stress and apoptotic biomarkers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505801/
https://www.ncbi.nlm.nih.gov/pubmed/31067255
http://dx.doi.org/10.1371/journal.pone.0216301
work_keys_str_mv AT elawdansallya regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers
AT abdelrahmanrehabf regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers
AT ibrahimhebam regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers
AT hegazyrehabr regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers
AT elmarasysalmaa regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers
AT badawimanal regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers
AT arbidmahmouds regressionoffibrosisbycilostazolinaratmodelofthioacetamideinducedliverfibrosisupregulationofhepaticcampandmodulationofinflammatoryoxidativestressandapoptoticbiomarkers